Anzeige
Meldung des Tages: Unglaubliche News: Nasdaq-Smallcap – Diese KI erkennt, was kein Labor sehen kann!

Alkermes News

Aktie
WKN:  A1JKVH ISIN:  IE00B56GVS15 US-Symbol:  ALKS
28,64 $
+0,295 $
+1,04%
24,654 € 06.03.26
Depot/Watchlist
Marktkapitalisierung *
3,94 Mrd. €
Streubesitz
100,00%
KGV
-
Index-Zuordnung
-

Alkermes News

12.12.25 - PR Newswire
Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL
Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel ...
19.11.25 - PR Newswire
Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc PR Newswire
19.11.25 - PR Newswire
Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc PR Newswire
14.11.25 - PR Newswire
Alkermes Response to Avadel Announcement
Alkermes Response to Avadel Announcement PR Newswire
14.11.25 - PR Newswire
Alkermes Response to Avadel Announcement
Alkermes Response to Avadel Announcement PR Newswire
12.11.25 - PR Newswire
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-​Daily Alixorexton in Patients With Narcolepsy Type 2 PR Newswire
12.11.25 - PR Newswire
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-​Daily Alixorexton in Patients With Narcolepsy Type 2 PR Newswire
06.11.25 - PR Newswire
Alkermes to Participate in Two Upcoming Investor Conferences
Alkermes to Participate in Two Upcoming Investor Conferences PR Newswire
06.11.25 - PR Newswire
Alkermes to Participate in Two Upcoming Investor Conferences
Alkermes to Participate in Two Upcoming Investor Conferences PR Newswire
05.11.25 - PR Newswire
FORM 8.1(a) & (b) (Opening Position Disclosure)
FORM 8.1(a) & (b) (Opening Position Disclosure) PR Newswire
05.11.25 - PR Newswire
FORM 8.1(a) & (b) (Opening Position Disclosure)
FORM 8.1(a) & (b) (Opening Position Disclosure) PR Newswire
28.10.25 - PR Newswire
Alkermes plc Reports Third Quarter 2025 Financial Results
Alkermes plc Reports Third Quarter 2025 Financial Results PR Newswire
28.10.25 - PR Newswire
Alkermes plc Reports Third Quarter 2025 Financial Results
Alkermes plc Reports Third Quarter 2025 Financial Results PR Newswire
22.10.25 - PR Newswire
Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc PR Newswire
22.10.25 - PR Newswire
Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc PR Newswire
20.10.25 - PR Newswire
Alkermes to Report Third Quarter Financial Results on October 28, 2025
Alkermes to Report Third Quarter Financial Results on October 28, 2025 PR Newswire
20.10.25 - PR Newswire
Alkermes to Report Third Quarter Financial Results on October 28, 2025
Alkermes to Report Third Quarter Financial Results on October 28, 2025 PR Newswire
12.09.25 - PR Newswire
Alkermes Appoints Joshua Reed as Chief Financial Officer
Alkermes Appoints Joshua Reed as Chief Financial Officer PR Newswire
12.09.25 - PR Newswire
Alkermes Appoints Joshua Reed as Chief Financial Officer
Alkermes Appoints Joshua Reed as Chief Financial Officer PR Newswire
11.09.25 - PR Newswire
Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program
Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program PR Newswire

Newssuche

Videos

newspaper
04.03.26 0,00%
ROHÖL mit Ziel MINUS 40$?!?
Fundierte Strategien für den Handel der wichtigen News in einem Seminarpaket, plus transparenter ... Mehr »